Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

Authors

  • Fariba Navid MD,

    Corresponding author
    1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
    2. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
    • Department of Oncology, St. Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, TN 38105
    Search for more papers by this author
    • Fax: (901) 521-9005

  • Jennifer Reikes Willert MD,

    1. Department of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Rady Children's Hospital, University of California at San Diego, San Diego, California
    Search for more papers by this author
  • M. Beth McCarville MD,

    1. Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
    2. Department of Radiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Search for more papers by this author
  • Wayne Furman MD,

    1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
    2. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
    Search for more papers by this author
  • Amy Watkins MS,

    1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
    Search for more papers by this author
  • William Roberts MD,

    1. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
    Search for more papers by this author
  • Najat C. Daw MD

    1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
    2. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
    Search for more papers by this author

Abstract

BACKGROUND.

The combination of gemcitabine and docetaxel has demonstrated promise in sarcomas diagnosed in adults. In the current study, the toxicity and efficacy of this combination were evaluated in pediatric sarcomas.

METHODS.

A retrospective case review of 22 patients with recurrent or refractory bone or soft-tissue sarcomas who received gemcitabine (at a dose of 675 mg/m2 intravenously on Days 1 and 8) and docetaxel (at a dose of 75–100 mg/m2 intravenously on Day 8) was undertaken.

RESULTS.

The patients (ages 8–23 years) received a total of 109 courses of chemotherapy (median, 4 courses; range, 1–13 courses). Seventeen patients had osteosarcoma, 2 patients had Ewing sarcoma family of tumors (ESFT), 1 patient had a malignant fibrous histiocytoma (MFH), 1 patient had a chondrosarcoma, and 1 patient had an undifferentiated sarcoma. Of the 14 patients evaluable for response, the patient with an MFH achieved a complete response (CR), 3 patients with osteosarcoma achieved a partial response (PR), and 2 patients (1 with ESFT and 1 with osteosarcoma) had stable disease (SD). The overall objective response (CR + PR) rate was 29%. Median duration of response (CR + PR + SD) was 4.8 months (range, 1.6-13 months). The toxicity was manageable and consisted primarily of thrombocytopenia and neutropenia.

CONCLUSIONS.

In the current study, gemcitabine in combination with docetaxel was found to be well tolerated and demonstrated antitumor activity in children and adolescents with recurrent or refractory osteosarcoma and MFH. Further evaluation of this drug combination is warranted in these patients. Cancer 2008. © 2008 American Cancer Society.

Ancillary